Analysis
Analysis
Recursion buys time to 2029, two share sales at a time
Recursion sold 85 million new shares in about four months, through its ATM and a $200M follow-on, to fund runway into 2029, and holders should ask why.
Analysis: opinion, not investment advice
Recursion Pharmaceuticals (RXRX) now says its cash lasts into 2029. The claim rests on real news: clinical data for two drugs and an option exercise by Sanofi arrived on the same day in October. The less advertised part is how the runway was bought. Between July and mid-October the company issued about 85m new shares through two different doors, one quiet and one loud. Shareholders who read only the headline deal saw half of it.
Our news desk covered the $200m offering and its discount on the day. This piece looks at the whole quarter.
The quiet door
In February Recursion filed a prospectus for an at-the-market (ATM) programme of up to $300m with TD Cowen as sales agent. An ATM lets a company dribble shares into the market at prevailing prices, with no announcement per sale. In the quarter to September 30th Recursion used it to sell 23,696,330 shares for about $86m in net proceeds, a fact disclosed in the October prospectus rather than in a release of its own. That implies a net price of about $3.63 a share, our calculation from the disclosed net proceeds; the filing does not give the gross price per share.
The loud door
On October 15th the company priced 61,540,000 shares at $3.25, raising about $200m gross. The final prospectus puts the last sale before pricing at $3.74, so buyers got about 13% off, and the underwriters took $0.195 a share, or 6%. Leerink Partners, Goldman Sachs, Morgan Stanley and Evercore were joint bookrunners and Needham was lead manager. The company named Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest and Driehaus Capital Management among the buyers.
Put the two together and roughly 85m shares were issued in about four months, for roughly $274m of net proceeds by our sum of the two figures. The preliminary cash figure of about $561m at September 30th already included the ATM money; the follow-on came on top.
What the money is for
Recursion's own list is specific, which is to its credit. The prospectus says the proceeds will fund a registrational study of REC-4881 in familial adenomatous polyposis (FAP) and dose expansion for REC-1245 in solid tumours, plus platform work and "runway extension". The October release reported a 47% median reduction in polyp burden after 12 weeks in adults with FAP, with the registrational trial targeted for the second half of 2027, pending talks with the FDA. Sanofi's option on an inflammatory-disease candidate is a vote of confidence in the platform, and under the collaboration Sanofi funds and leads development from here.
Those results are the case for patience with an AI-native drug developer that now has human data.
The criticism
The question for the board and for the chief executive, Najat Khan, and the chief financial officer, Ben Taylor (both sign the company's 10-Q), is about sequence. Management chose to sell shares through the ATM during a quarter in which the REC-4881 and REC-1245 updates and the Sanofi milestone had not yet been published. It then priced the follow-on at a discount alongside that news. Nothing in the filings suggests this broke any rule; ATM sales under an effective shelf are routine. But holders who bought in the summer took dilution before the data that might have justified a better price, and the larger sale still went off well below market.
Comparables sharpen the point. Absci (ABSI), another AI-led drug developer, sold 13,495,277 shares in June at $7.41, and its prospectus supplement gives $7.41 as the last reported sale price on June 23rd, so there was no discount to that price. Eli Lilly was allocated 5,398,111 of the shares, or $40m. Viking Therapeutics (VKTX) priced 7,857,143 shares at $35.00 in September, two days after its maintenance data; its prospectus supplement gives a last reported sale price of $40.85 on September 22nd, which puts the discount at about 14% by our arithmetic. Recursion priced 61,540,000 shares at $3.25 against a $3.74 last reported sale on October 14th, about 13% below. On these figures Recursion's discount was close to Viking's and well wide of Absci's, whose raise had a strategic buyer taking 40% of the shares.
Board leadership is the other open point. Recursion's 2026 proxy said Christopher Gibson, then chair and a former chief executive, would leave the board after the 2026 annual meeting, and that Robert Hershberg, vice chair and lead independent director, would continue as lead independent director until the board appointed a new chair. The June 17th meeting results list Najat Khan and Franziska Michor as the directors elected. The latest filings we found, up to the October 15th 8-K, disclose no new chair. Shareholders would benefit from the company stating who chaired the board that approved a $200m sale below market.
What to watch
Investors should watch whether the ATM keeps running after the follow-on, since the prospectus leaves room for it, and what share count sits behind "runway into 2029", which the company has not published. The FDA discussions on REC-4881 matter most, since a registrational trial is the largest named use of the new money.
Recursion has done the hard part of turning an AI platform into clinical evidence. The next test is whether it can raise money on that evidence without handing so much of the upside to buyers who arrive on the day.
Sources: Recursion pricing release (8-K exhibit 99.4), preliminary and final 424B5 prospectus supplements, ATM prospectus, Q2 10-Q, 2026 proxy, June 17th 8-K, October 15th business update, all linked above. Auditor: PricewaterhouseCoopers LLP, ratified at the June 17th meeting.
Sources
- into 2029
- at-the-market (ATM) programme of up to $300m
- 23,696,330 shares for about $86m in net proceeds
- priced 61,540,000 shares at $3.25
- final prospectus
- funds and leads development
- sign the company's 10-Q
- at $7.41, equal to its last reported sale price
- 2026 proxy
- June 17th meeting results
- October 15th 8-K
Disclosures
- Every figure carries the as-of date of its source.
- This analysis was drafted with AI tools from the company's own filings, FDA documents and trial registries. Every number is checked against its source and an editor reviews the piece before it is published.
- Our method and conflicts policy: aibio.space/disclosures/
As of , aibio.space has received no compensation from, and has no paid relationship with, the company covered.
Investor Chat
Loading posts…
aibio